DME in the Real World: Treatments Past, Present, and Future
Release Date: February 28, 2018
Expiration Date: February 28, 2019
This educational activity is provided by Dannemiller
Supported by an education grant from Allergan
Ophthalmologists and Retina Specialists
Upon completion of this activity, the participant should be able to:
- Review the history of therapeutic options for DME.
- Explain the role inflammation plays in the pathogenesis of DME.
- Discuss the current landscape of DME including pivotal trials and subset analyses (RISE/RIDE, VIVID/VISTA, MEAD, FAME, EARLY).
- Review real-world studies and current phase IV studies involving corticosteroids, including REINFORCE.
- Describe large database and practice survey studies to better identify real-world treatment patterns.
- Discuss clinical trials currently in development for treatment of DME including: RUBY, BOULEVARD, CLS-1004.
Statement of Need
In the field of DME, continuing education is essential to ensure that ophthalmologists and retinal specialists are familiar with the most accurate and recent evidence-based treatments, including the mechanisms of action for each of those therapies.
Method of Participation
This activity should take approximately two hours to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through February 28, 2019. No credit will be given after this date. There is no fee to participate in this activity.
In the event you have questions about this activity or are unable to retrieve the certificate, please email firstname.lastname@example.org and a certificate will be emailed within 2 weeks.
- Computer, tablet, or smartphone with internet access
- HTML5 compatible browser or Adobe Flash Player
In support of improving patient care, Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Michael Singer, M.D.
Associate Clinical Professor
University of Texas, San Antonio
San Antonio, Texas
Seenu Hariprasad, M.D.
Professor of Ophthalmology
Chief, Viteroretinal Service
Director Clinical Research
University of Chicago
Szilard Kiss, MD
Chief, Retina Service
Director, Clinical Research
Associate Professor of Ophthalmology
Weill Cornell Medical College
New York, New York
Charles Wychkoff, M.D.
Retina Consultants of Houston
Blanton Eye Institute
Houston Methodist Hospital
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE activity must disclose all financial relationships they have with a commercial interest.
The following faculty have financial relationships with commercial interests: Michael Singer, M.D.: Speaker--Allergan, Genentech, Regeneron; Consultant--Allergan, Genentech, Santen, Aerpio; Advisory Board--Allergan, Genentech, Regeneron, Santen, Aerpio; Investigator--Allergan, Genentech, Regeneron, Santen, Optos, Aerpio; Seenu Hariprasad, M.D.: Speaker--Alcon, Regeneron; Consultant--Alcon, Regeneron, Allergan, Bayer, Alimera, Sandoz, Clearside Biomedical; Advisory Board--Alcon, Regeneron, Allergan; Stockholder--Clearside Biomedical; Szilard Kiss, M.D.:Consultant--Alimera, Allergan, Genentech/Roche, Regeneron, Optos ; and Charles Wyckoff, M.D.:Speaker--Allergan; Consultant--Alcon, Alimera, Allergan; Investigator--Aerpio, Alcon, Aldevra, Allergro, Allergan.
Alex Yuan, M.D., content reviewer; Melanie Romero, Audio Video; Myra Garcia, Business Development; Tiffany Oliphint and Jennifer Hodge, Dannemiller Project Manager have no financial relationships with commercial interests.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or Allergan. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.